Which has better earnings & valuation, VLG or PXS?

Venture Life Group has higher revenue and earnings than Provexis. Provexis is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Venture Life Group £35.17M 2.29 £747.21K £4.37 15.26 Provexis £871.27K 30.96 -£619.15K -£0.02 N/A

Which has better valuation & earnings, PXS or BVXP?

Bioventix has higher revenue and earnings than Provexis. Provexis is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Provexis £871.27K 30.96 -£619.15K -£0.02 N/A Bioventix £12.54M 7.35 £8.12M £140.52 12.55

Is PXS or BVXP more profitable?

Bioventix has a net margin of 59.30% compared to Provexis' net margin of -69.30%. Bioventix's return on equity of 65.83% beat Provexis' return on equity. Company Net Margins Return on Equity Return on Assets Provexis -69.30% -49.45% -56.14% Bioventix 59.30% 65.83% 54.07%

Which has stronger valuation and earnings, PXS or ORPH?

Open Orphan has higher revenue and earnings than Provexis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Provexis £871.27K 30.96 -£619.15K -£0.02 N/A Open Orphan £34.71M 0.00 N/A N/A N/A

Is PXS or ORPH more profitable?

Open Orphan has a net margin of 0.00% compared to Provexis' net margin of -69.30%. Open Orphan's return on equity of 0.00% beat Provexis' return on equity. Company Net Margins Return on Equity Return on Assets Provexis -69.30% -49.45% -56.14% Open Orphan N/A N/A N/A

Do analysts rate PXS or EAH?

ECO Animal Health Group has a consensus target price of GBX 160, indicating a potential upside of 59.36%. Given ECO Animal Health Group's stronger consensus rating and higher possible upside, analysts plainly believe ECO Animal Health Group is more favorable than Provexis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Provexis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ECO Animal Health Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts prefer PXS or MRK?

Marks Electrical Group has a consensus price target of GBX 52.50, suggesting a potential upside of 15.51%. Given Marks Electrical Group's stronger consensus rating and higher possible upside, analysts plainly believe Marks Electrical Group is more favorable than Provexis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Provexis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Marks Electrical Group 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Provexis (PXS) Competitors

GBX 1.15 +0.03 (+2.22%)

As of 08/21/2026 11:42 AM Eastern

Compare

PXS vs. VLG, BVXP, ORPH, EAH, and MRK

Should you buy Provexis stock or one of its competitors? Provexis's main competitors and comparable companies include Venture Life Group (VLG), Bioventix (BVXP), Open Orphan (ORPH), ECO Animal Health Group (EAH), and Marks Electrical Group (MRK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Provexis compare to Venture Life Group?

Venture Life Group (LON:VLG) and Provexis (LON:PXS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

21.9% of Venture Life Group shares are held by institutional investors. Comparatively, 7.9% of Provexis shares are held by institutional investors. 7.5% of Venture Life Group shares are held by insiders. Comparatively, 11.8% of Provexis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Venture Life Group has higher revenue and earnings than Provexis. Provexis is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venture Life Group	£35.17M	2.29	£747.21K	£4.37	15.26
Provexis	£871.27K	30.96	-£619.15K	-£0.02	N/A

Venture Life Group has a beta of 0.217, suggesting that its share price is 78% less volatile than the broader market. Comparatively, Provexis has a beta of 0.672, suggesting that its share price is 33% less volatile than the broader market.

Venture Life Group has a net margin of 17.42% compared to Provexis' net margin of -69.30%. Venture Life Group's return on equity of 7.82% beat Provexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venture Life Group	17.42%	7.82%	1.56%
Provexis	-69.30%	-49.45%	-56.14%

In the previous week, Venture Life Group had 1 more articles in the media than Provexis. MarketBeat recorded 1 mentions for Venture Life Group and 0 mentions for Provexis. Venture Life Group's average media sentiment score of 0.00 equaled Provexis'average media sentiment score.

Company	Overall Sentiment
Venture Life Group	Neutral
Provexis	Neutral

Summary

Venture Life Group beats Provexis on 9 of the 12 factors compared between the two stocks.

How does Provexis compare to Bioventix?

Provexis (LON:PXS) and Bioventix (LON:BVXP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

7.9% of Provexis shares are owned by institutional investors. Comparatively, 20.6% of Bioventix shares are owned by institutional investors. 11.8% of Provexis shares are owned by insiders. Comparatively, 6.2% of Bioventix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Provexis has a beta of 0.672, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Bioventix has a net margin of 59.30% compared to Provexis' net margin of -69.30%. Bioventix's return on equity of 65.83% beat Provexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Provexis	-69.30%	-49.45%	-56.14%
Bioventix	59.30%	65.83%	54.07%

In the previous week, Provexis' average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company	Overall Sentiment
Provexis	Neutral
Bioventix	Neutral

Bioventix has higher revenue and earnings than Provexis. Provexis is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Provexis	£871.27K	30.96	-£619.15K	-£0.02	N/A
Bioventix	£12.54M	7.35	£8.12M	£140.52	12.55

Summary

Bioventix beats Provexis on 8 of the 11 factors compared between the two stocks.

How does Provexis compare to Open Orphan?

Provexis (LON:PXS) and Open Orphan (LON:ORPH) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

In the previous week, Provexis' average media sentiment score of 0.00 equaled Open Orphan'saverage media sentiment score.

Company	Overall Sentiment
Provexis	Neutral
Open Orphan	Neutral

Open Orphan has a net margin of 0.00% compared to Provexis' net margin of -69.30%. Open Orphan's return on equity of 0.00% beat Provexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Provexis	-69.30%	-49.45%	-56.14%
Open Orphan	N/A	N/A	N/A

7.9% of Provexis shares are held by institutional investors. 11.8% of Provexis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Open Orphan has higher revenue and earnings than Provexis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Provexis	£871.27K	30.96	-£619.15K	-£0.02	N/A
Open Orphan	£34.71M	0.00	N/A	N/A	N/A

Summary

Open Orphan beats Provexis on 5 of the 7 factors compared between the two stocks.

How does Provexis compare to ECO Animal Health Group?

Provexis (LON:PXS) and ECO Animal Health Group (LON:EAH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

In the previous week, Provexis' average media sentiment score of 0.00 equaled ECO Animal Health Group'saverage media sentiment score.

Company	Overall Sentiment
Provexis	Neutral
ECO Animal Health Group	Neutral

ECO Animal Health Group has higher revenue and earnings than Provexis. Provexis is trading at a lower price-to-earnings ratio than ECO Animal Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Provexis	£871.27K	30.96	-£619.15K	-£0.02	N/A
ECO Animal Health Group	£87.53M	0.77	£1.05M	£3.15	31.87

ECO Animal Health Group has a net margin of 2.50% compared to Provexis' net margin of -69.30%. ECO Animal Health Group's return on equity of 2.55% beat Provexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Provexis	-69.30%	-49.45%	-56.14%
ECO Animal Health Group	2.50%	2.55%	2.14%

Provexis has a beta of 0.672, indicating that its stock price is 33% less volatile than the broader market. Comparatively, ECO Animal Health Group has a beta of 0.71863484, indicating that its stock price is 28% less volatile than the broader market.

ECO Animal Health Group has a consensus target price of GBX 160, indicating a potential upside of 59.36%. Given ECO Animal Health Group's stronger consensus rating and higher possible upside, analysts plainly believe ECO Animal Health Group is more favorable than Provexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Provexis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ECO Animal Health Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

7.9% of Provexis shares are held by institutional investors. Comparatively, 40.8% of ECO Animal Health Group shares are held by institutional investors. 11.8% of Provexis shares are held by insiders. Comparatively, 11.3% of ECO Animal Health Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

ECO Animal Health Group beats Provexis on 12 of the 14 factors compared between the two stocks.

How does Provexis compare to Marks Electrical Group?

Provexis (LON:PXS) and Marks Electrical Group (LON:MRK) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Marks Electrical Group has a consensus price target of GBX 52.50, suggesting a potential upside of 15.51%. Given Marks Electrical Group's stronger consensus rating and higher possible upside, analysts plainly believe Marks Electrical Group is more favorable than Provexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Provexis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Marks Electrical Group	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Provexis' average media sentiment score of 0.00 equaled Marks Electrical Group'saverage media sentiment score.

Company	Overall Sentiment
Provexis	Neutral
Marks Electrical Group	Neutral

Provexis has a beta of 0.672, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Marks Electrical Group has a beta of 0.577, suggesting that its stock price is 42% less volatile than the broader market.

Marks Electrical Group has a net margin of -0.39% compared to Provexis' net margin of -69.30%. Marks Electrical Group's return on equity of -4.18% beat Provexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Provexis	-69.30%	-49.45%	-56.14%
Marks Electrical Group	-0.39%	-4.18%	0.91%

Marks Electrical Group has higher revenue and earnings than Provexis. Marks Electrical Group is trading at a lower price-to-earnings ratio than Provexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Provexis	£871.27K	30.96	-£619.15K	-£0.02	N/A
Marks Electrical Group	£107.93M	0.44	£426.93K	-£0.40	N/A

7.9% of Provexis shares are held by institutional investors. Comparatively, 0.2% of Marks Electrical Group shares are held by institutional investors. 11.8% of Provexis shares are held by company insiders. Comparatively, 75.4% of Marks Electrical Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Marks Electrical Group beats Provexis on 9 of the 14 factors compared between the two stocks.

Get Provexis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PXS vs. The Competition

Export

Metric	Provexis	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£26.39M	£12.57B	£7.37B	£2.54B
Dividend Yield	5.06%	2.61%	2.53%	6.17%
P/E Ratio	-57.50	789.80	272.60	367.57
Price / Sales	30.96	762.12	623.83	83,481.74
Price / Cash	N/A	96.77	78.62	27.89
Price / Book	134.07	11.89	13.05	7.19
Net Income	-£619.15K	£2.81B	£3.47B	£5.89B
7 Day Performance	-5.66%	1.77%	2.09%	0.30%
1 Month Performance	N/A	3.85%	6.64%	3.31%
1 Year Performance	62.89%	6.56%	25.02%	22.13%

Provexis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PXS Provexis	N/A	GBX 1.15 +2.2%	N/A	+62.9%	£26.39M	£871.27K	N/A	4	Gap Up
VLG Venture Life Group	N/A	GBX 67.75 -0.4%	N/A	+15.2%	£81.92M	£35.17M	15.50	165	News Coverage
BVXP Bioventix	N/A	GBX 1,538 +2.5%	N/A	-29.4%	£80.36M	£12.54M	10.95	12
ORPH Open Orphan	N/A	N/A	N/A	N/A	£67.09M	£34.71M	N/A	179
EAH ECO Animal Health Group	N/A	GBX 100.15 -2.3%	GBX 160 +59.8%	+37.0%	£66.82M	£87.53M	31.79	234	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:PXS) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Provexis (PXS) Competitors

PXS vs. VLG, BVXP, ORPH, EAH, and MRK

How does Provexis compare to Venture Life Group?

Summary

How does Provexis compare to Bioventix?

Summary

How does Provexis compare to Open Orphan?

Summary

How does Provexis compare to ECO Animal Health Group?

Summary

How does Provexis compare to Marks Electrical Group?

Summary

Media Sentiment Over Time

PXS vs. The Competition

Provexis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Provexis (PXS) Competitors

PXS vs. VLG, BVXP, ORPH, EAH, and MRK

How does Provexis compare to Venture Life Group?

Do institutionals and insiders believe in VLG or PXS?

Which has better earnings & valuation, VLG or PXS?

Which has more risk and volatility, VLG or PXS?

Is VLG or PXS more profitable?

Does the media favor VLG or PXS?

Summary

How does Provexis compare to Bioventix?

Do institutionals and insiders hold more shares of PXS or BVXP?

Which has more risk and volatility, PXS or BVXP?

Is PXS or BVXP more profitable?

Does the media refer more to PXS or BVXP?

Which has better valuation & earnings, PXS or BVXP?

Summary

How does Provexis compare to Open Orphan?

Does the media refer more to PXS or ORPH?

Is PXS or ORPH more profitable?

Do institutionals & insiders hold more shares of PXS or ORPH?

Which has stronger valuation and earnings, PXS or ORPH?

Summary

How does Provexis compare to ECO Animal Health Group?

Does the media refer more to PXS or EAH?

Which has higher valuation & earnings, PXS or EAH?

Is PXS or EAH more profitable?

Which has more risk & volatility, PXS or EAH?

Do analysts rate PXS or EAH?

Do insiders and institutionals believe in PXS or EAH?

Summary

How does Provexis compare to Marks Electrical Group?

Do analysts prefer PXS or MRK?

Does the media refer more to PXS or MRK?

Which has more volatility and risk, PXS or MRK?

Is PXS or MRK more profitable?

Which has stronger valuation and earnings, PXS or MRK?

Do insiders and institutionals believe in PXS or MRK?

Summary

Media Sentiment Over Time

PXS vs. The Competition

Provexis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools